Fulcrum Therapeutics logo
Fulcrum Therapeutics
FULC | NASDAQ
Chart Builder DCF Calculator
$3.71
-$0.06 (-1.59%)
At close: Nov 16, 2026, 4:00 PM ET
$3.72
+$0.01 (+0.27%)
After-hours: Nov 16, 2026, 5:58 PM ET

Fulcrum Therapeutics Company Profile

Company profile explained

Company Profile

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy, and FTX-6058, an orally administered fetal hemoglobin inducer for sickle cell disease and related hemoglobinopathies, such as beta-thalassemia. Beyond these, Fulcrum is actively engaged in discovering new drug targets for various rare conditions, encompassing neuromuscular, muscular, central nervous system, and hematologic disorders, alongside cardiomyopathies and pulmonary diseases. The company has established key collaborations, notably a research and discovery partnership with Acceleron Pharma Inc. to identify biological targets within the pulmonary disease area, and a strategic licensing and development agreement with MyoKardia, Inc. focused on novel targeted therapies for genetic cardiomyopathies. Incorporated in 2015, Fulcrum Therapeutics, Inc. maintains its headquarters in Cambridge, Massachusetts.

Key Executives

Name Position
Alexander C. Sapir Chief Executive Officer, President & Director
Curtis G. Oltmans Chief Legal Officer, Head of External Affairs & Corporate Secretary
Alan A. Musso CFO, Treasurer & Principal Accounting Officer
Bobby Riehle Head of Program Strategy & Vice President
Bradley E. Bernstein Founder
Danny Reinberg Founder
Iain Fraser DPHIL Senior Vice President of Early Development
Lisa Percival Chief Regulatory & Quality Assurance Officer
Michael R. Green Founder
Rudolf Jaenisch Founder
Tsun-Huei Lee Founder

Latest SEC Filings

Date Type Title
Oct 28, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Oct 27, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Oct 20, 2026 S-4/A [Amend] Filing
Oct 08, 2026 S-4/A [Amend] Filing
Sep 02, 2026 S-4 Filing
Aug 17, 2026 425 Filing
Aug 17, 2026 425 Filing
Aug 17, 2026 425 Filing
Aug 17, 2026 8-K Current Report
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
View All SEC Filings ➞
Fulcrum Therapeutics
Fulcrum Therapeutics logo
Country United States
IPO Date Jul 18, 2019
Industry Biotechnology
Sector Healthcare
Employees 9
CEO Alexander C. Sapir

Contact Details

26 Landsdowne Street Cambridge, Massachusetts 02139 United States

Stock Details

Ticker Symbol FULC
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001680581
CUSIP Number 359616109
ISIN Number US3596161097
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.